Record-Low Cash Burn and Strategic Advances Highlight Butterfly Network’s Third Quarter

Cash Efficiency Hits New Record as Company Maintains Revenue Growth

Butterfly Network’s third quarter results paint a picture of financial discipline paired with platform innovation. The company achieved quarterly revenue of $21.49 million, reflecting 5% year-over-year growth despite what leadership described as a seasonally softer period. More striking, Butterfly set a company record for quarterly cash usage, trimming cash burn to just $3.9 million—a positive shift from prior quarters and a key operational milestone.

AI Progress and Platform Ecosystem Unlock New Clinical and Commercial Value

The company is pressing forward on multiple technology and product fronts. Notable achievements this quarter include the development of the P5.1 chip and the initiation of a next-generation Apollo AI chip—expected to further expand AI capabilities at the edge. The company’s Compass AI platform is advancing, and its Butterfly Garden saw the launch of the first FDA-cleared third-party app, enabling AI-guided echo exams. In addition, Butterfly rolled out an AI-powered Gestational Age Calculator for maternal health in Malawi and Uganda, already submitted to the U.S. FDA for review.

Clinical evidence underpins Butterfly’s impact: A Rutgers-led study found that Butterfly’s Auto B-line Counter reduced patient hospital stays and generated over $750,000 in direct cost savings across 246 bed-days—a real-world testament to the platform’s potential to improve healthcare workflows and reduce costs.

Gross Margins and Operating Expense Trends Mixed—Non-GAAP Margins Climb as Inventory Is Rationalized

GAAP gross margin fell sharply to -17.5%, impacted by a one-time $17.49 million inventory write-down. However, the underlying business shows more strength: adjusted gross margin (which excludes these non-recurring charges) rose to 63.9% from 60.0% a year earlier, reflecting higher selling prices and more efficient software amortization.

Total operating expenses were $31.38 million (up 6% year-over-year), but non-GAAP expenses remained essentially flat—highlighting disciplined expense management. The company posted a net loss of $33.97 million, wider than last year, but adjusted EPS improved to $(0.04) versus $(0.05) in the prior-year period.

Guidance Reaffirmed as Butterfly Banks on Innovation

Management reaffirmed its full-year revenue guidance at $91–95 million, implying about 13% growth, and narrowed adjusted EBITDA loss expectations to $32–35 million. With $144.23 million in cash on the balance sheet and clear visibility into pipeline and platform progress, Butterfly has room to continue strategic investment and operational improvement. Ongoing initiatives in AI, cloud, and clinical validation signal confidence in sustained momentum as 2025 closes.

Takeaway: Long-Term Innovation, Operational Grit, and Clinical Proof Underpin Butterfly’s Next Phase

Butterfly Network’s third quarter was defined by operational resilience, continued platform progress, and mounting clinical validation for its products. Record-low cash usage, climbing non-GAAP margins, and expanding AI and cloud initiatives suggest a business strengthening beneath the surface. As Butterfly approaches new regulatory and product milestones, the company’s commitment to democratizing ultrasound technology—and creating a global platform—bears watching by investors and healthcare technologists alike.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI